References
1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. Journal of Clinical Oncology. 1998;16(8):2780-95.
2. Gratzinger D, Zhao S, Tibshirani RJ, Hsi ED, Hans CP, Pohlman B, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Laboratory investigation. 2008;88(1):38-47.
3. Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, et al. Angiogenic growth factors and endostatin in non‐Hodgkin’s lymphoma. British journal of haematology. 1999;106(2):504-9.
4. Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood, The Journal of the American Society of Hematology. 2013;121(26):5192-202.
5. Scarpino S, Di Napoli A, Taraboletti G, Cancrini A, Ruco LP. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP‐1) expression in thyroid papillary carcinoma cells. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2005;205(1):50-6.
6. Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-β. The American journal of pathology. 2004;165(2):541-52.
7. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. Journal of clinical oncology. 2007;25(5):579-86.
8. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nature reviews Drug discovery. 2007;6(4):273-86.
9. Paydas S, Ergin M, Seydaoglu G, Erdogan S, Yavuz S. Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leukemia research. 2009;33(12):1627-35.
10. Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood, The Journal of the American Society of Hematology. 2000;96(9):3181-7.
11. Doussis‐Anagnostopoulou IA, Talks KL, Turley H, Debnam P, Tan DC, Mariatos G, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin–Reed–Sternberg cells in Hodgkin’s disease. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2002;197(5):677-83.
12. Foss Hd, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman’s disease. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 1997;183(1):44-50.
13. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. The Journal of clinical investigation. 2000;106(4):511-21.
14. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas J, Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood. 2006;107(4):1608-16.
15. Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge Ø, Pedersen LM, et al. High serum vascular endothelial growth factor level is an adverse prognostic factor for high‐risk diffuse large B‐cell lymphoma patients treated with dose‐dense chemoimmunotherapy. European journal of haematology. 2012;89(5):395-402.
16. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood, The Journal of the American Society of Hematology. 2000;96(12):3712-8.
17. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin’s lymphoma. Leukemia & lymphoma. 2003;44(12):2089-93.
18. Tzankov A, Heiss S, Ebner S, Sterlacci W, Schaefer G, Augustin F, et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. Journal of Clinical Pathology. 2007;60(5):476-82.
19. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. The American journal of pathology. 2006;169(6):2054-65.
20. Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, et al. Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia. 2009;11(6):594-604.
21. Sano H, Ueda Y, Takakura N, Takemura G, Doi T, Kataoka H, et al. Blockade of platelet-derived growth factor receptor-β pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. The American journal of pathology. 2002;161(1):135-43.
22. Albo D, Tuszynski G. Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. Journal of Surgical Research. 2004;120(1):21-6.
23. Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U. Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin’s lymphomas. Leukemia research. 2008;32(2):243-50.